

January 30, 2018
Carla Ferra Maass
VidaCel Banco Publico
Juan XXIII 6323
Vitacura
Santiago de Chile, CL

Dear Carla Ferrada Maass,

Thank you for submitting qualification materials to participate as a cord blood bank in the National Marrow Donor Program® (NMDP) Investigational New Drug (IND). I am pleased to notify you that *VidaCel Banco Publico* has qualified to participate under the NMDP Investigational New Drug (IND) Application: *A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Donor Umbilical Cord Blood Transplantation*.

I would like to offer my congratulations to your facility. We greatly appreciate your collaboration in our efforts to ensure access to cord blood units for patients worldwide.

I would like to take the opportunity to provide you with a few reminders about NMDP IND requirements:

- Registration with the FDA is currently not required. If your bank chooses to register with the FDA and lists me as the U.S. Agent on the FDA Establishment Registration Form, cord blood shipments to the U.S. must be facilitated by the NMDP.
- If a U.S. transplant center wants to access units from your bank directly, your bank will need to qualify under another IND. Your institution will not be covered by the NMDP IND.
- There is an annual NMDP IND renewal qualification process. The NMDP membership staff will contact you next year with renewal materials.

We look forward to working with your cord blood bank to achieve our shared mission of saving lives.

For questions or concerns, contact the Cord Blood Bank Liaisons at cordliaisons@nmdp.org.

Best regards,



John Miller, M.D., Ph.D.
National Marrow Donor Program
Vice President and Senior Medical Director,
Medical, Quality, & Regulatory
NMDP IND Principal Investigator

c: Lori Hanley, Senior Regulatory Compliance Specialist
Merry Duffy, Director, Cord Blood Operations